Singapore markets open in 6 hours 54 minutes
Straits Times Index
3,137.54 +25.89 (+0.83%) S&P 500
3,898.75 -12.99 (-0.33%) Dow
31,416.58 -84.10 (-0.27%) Nasdaq
11,527.72 -79.90 (-0.69%) BTC-USD
20,729.73 -505.80 (-2.38%) CMC Crypto 200
451.35 -10.45 (-2.26%)
SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:06PM EDT. Market open.
| Previous close | 25.65 |
| Open | 25.78 |
| Bid | 27.27 x 900 |
| Ask | 27.31 x 1200 |
| Day's range | 24.79 - 27.47 |
| 52-week range | 13.60 - 89.75 |
| Volume | |
| Avg. volume | 1,207,272 |
| Market cap | 1.354B |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.23 |
| Earnings date | 02 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 76.25 |
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
- Zacks
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
- Zacks
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
© 2022 Yahoo. All rights reserved.
